The effect of virtual reality technology on pain management in cancer patients

INTERVENTION: Control Group:Standardized pain management nursing care;Trial Group 1 (VR Distraction Mechanism Group):Standardized pain management nursing care + VR distraction mechanism intervention (using PICO 4 to enter exploratory virtual travel scenarios to divert attention, each session lasting 20‐30 minutes, once daily for 3 weeks);Trial Group 2 (Mindfulness‐Based Emotional Regulation Mechanism Group):Standardized pain management nursing care + VR mindfulness‐based emotional regulation intervention (using PICO 4 to enter virtual meditation scenarios with mindful breathing guidance, each session lasting 20‐30 minutes, once daily for 3 weeks); CONDITION: Cancer‐related pain PRIMARY OUTCOME: Cortisol level; SECONDARY OUTCOME: Pain relief rate;Reduction rate in analgesic drug usage;Incidence of opioid‐induced hyperalgesia (OIH);Sleep quality;Quality of life; INCLUSION CRITERIA: 1. Adults (>=18 years) with a confirmed diagnosis of any malignancy who are experiencing cancer‐related pain; 2. Patients with a pain score >=4 (moderate to severe pain) who require pain management and are using opioid analgesics during the management process; 3. Patients who are conscious, with good language expression and comprehension ability, and able to cooperate with the study procedures; 4. Patients without severe cardiovascular or cerebrovascular diseases (such as unstable angina, heart failure, uncontrolled hypertension, history of stroke) or other conditions/comorbidities that may affect study safety; 5. Patients without contraindications to the use of VR devices (such as severe vertigo, history of epilepsy, severe visual or auditory impairment); 6. Patients who voluntarily participate in the study, provide informed consent, and sign the informed consent form.